Cited by 364Neurogenesis and neuroplasticity mechanismsNeonatal and fetal brain pathologyMultiple Sclerosis Research Studies

Axin2 as regulatory and therapeutic target in newborn brain injury and remyelination

Open access
Fancy, Stephen P J, Harrington, Emily P, Yuen, Tracy J, Silbereis, John C, Zhao, Chao, Baranzini, Sergio E, Bruce, Charlotte C, Otero, Jose J +4 more·2011·Nature Neuroscience

Abstract

Permanent damage to white matter tracts, comprising axons and myelinating oligodendrocytes, is an important component of brain injuries of the newborn that cause cerebral palsy and cognitive disabilities, as well as multiple sclerosis in adults. However, regulatory factors relevant in human developmental myelin disorders and in myelin regeneration are unclear. We found that AXIN2 was expressed in immature oligodendrocyte progenitor cells (OLPs) in white matter lesions of human newborns with neonatal hypoxic-ischemic and gliotic brain damage, as well as in active multiple sclerosis lesions in adults. Axin2 is a target of Wnt transcriptional activation that negatively feeds back on the pathway, promoting β-catenin degradation. We found that Axin2 function was essential for normal kinetics of remyelination. The small molecule inhibitor XAV939, which targets the enzymatic activity of tankyrase, acted to stabilize Axin2 levels in OLPs from brain and spinal cord and accelerated their differentiation and myelination after hypoxic and demyelinating injury. Together, these findings indicate that Axin2 is an essential regulator of remyelination and that it might serve as a pharmacological checkpoint in this process.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nn.2855

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • M2 depletion decreased the number of nodes of Ranvier, shown by reduced paranodal Caspr localization flanking nodal Ankyrin-G.

    “Second, we demonstrated a decrease in the number of nodes of Ranvier normally indicative of compact myelin27, 28 by showing reduced paranodal Caspr localization (flanking nodal Ankyrin-G) (Fig. 5g, h).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Fancy, S. P. J., Harrington, E. P., Yuen, T. J., Silbereis, J. C., Zhao, C., Baranzini, S. E., Bruce, C. C., Otero, J. J., Huang, E. J., Nusse, R., Franklin, R. J. M., & Rowitch, D. H.
Affiliations
  • Howard Hughes Medical Institute (US)
  • University of Cambridge (GB)
  • University of California, San Francisco (US)
Corresponding author
Rowitch, David H
Venue
Nature Neuroscience
Published
2011-06-26
Volume
14
Issue
8
Pages
1009-1016
ISSN
  • 1097-6256 (ISSN-L)
  • 1546-1726
OpenAlex
W2149924247
Cited by
349
References
37
Citations by year
2026: 10 · 2025: 17 · 2024: 15 · 2023: 16 · 2022: 10 · 2021: 20 · 2020: 20 · 2019: 16 · 2018: 25 · 2017: 35 · 2016: 26 · 2015: 36 · 2014: 42 · 2013: 35 · 2012: 21
FWCI
10.60
Type
journal article
Language
en
Open access
Locations
  • Nature Neuroscience (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • Howard Hughes Medical Institute
  • Parkinson's UK (G0909)
  • University of California, San Francisco
  • National Institute of Neurological Disorders and Stroke (NS047572, P01NS047572, NS040511, R01NS040511)
Topics
  • Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal and fetal brain pathology
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
Keywords
Axin2, remyelination, neonatal hypoxic-ischemic injury, oligodendrocyte precursor cells, tankyrase inhibition, XAV939, Wnt signaling, β-catenin degradation, myelination, multiple sclerosis, white matter lesions, oligodendrocyte differentiation, therapeutic target
MeSH terms
Oligodendrocyte Transcription Factor 2, Adult, Animals, Animals, Newborn, beta-Galactosidase, Brain Injuries, Cell Differentiation, Cells, Cultured, Cerebellum, Cerebral Cortex, Corpus Callosum, Cytoskeletal Proteins, Demyelinating Diseases, Disease Models, Animal, Dose-Response Relationship, Drug, Female, Gene Expression Regulation, Heterocyclic Compounds, 3-Ring, Humans, Infant, Newborn, Lysophosphatidylcholines, Male, Mice, Transgenic, Multiple Sclerosis, Myelin Proteins, Myelin Sheath, Nerve Tissue Proteins, Neurons, Oligodendroglia, Organ Culture Techniques, Postmortem Changes, Spinal Cord, Stem Cells, Ki-67 Antigen, Hypoxia-Ischemia, Brain, Microscopy, Electron, Transmission, Wnt Proteins, beta Catenin, Mice, Basic Helix-Loop-Helix Proteins, Axin Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review